Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.75    -0.375 (-2.65%)
Bid:
13.50
Ask:
14.00
Spread: 0.50 (3.704%)
Market Cap: £61.76m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Issue of Equity

9 Jul 2008 07:00

RNS Number : 6248Y
China Real Estate Opportunities Ltd
09 July 2008
 



China Real Estate Opportunities Limited 

Issue of Equity 

The Directors of China Real Estate Opportunities Limited ("CREO" or the "Company") announce that in respect of the period ended 31 December 2007, the manager is due a performance fee of £3.59 million.  The manager, which is entitled to receive up to half of the performance fee in cash, has elected to accept the whole of the fee in new CREO shares. Accordingly 420,653 new ordinary shares of no par value were issued to Treasury Holdings China Limited ("THCL") on 3 July 2008 equating to the performance fee of £3.52 million divided by the year end net asset value per share of £8.37.

An application has been made to the London Stock Exchange for the admission to AIM of those shares.

THCL and other related shareholders are deemed to be acting in concert for the purposes of the City Code on Take-overs and Mergers. Following the issue of these shares the aggregate shareholdings of those parties amounts to 24,098,927 ordinary shares representing 47.47 per cent. of the enlarged share capital of the Company. Shareholders have previously approved a waiver granted by the Panel on Take-overs and Mergers of any requirement under rule 9 of the Take-over Code for the parties acting in concert to make a bid for the Company.

Enquiries to: 

 

CREO 

Ray Horney Tel: + 44 (0) 1273 775 225 

 

Landsbanki Securities (UK) Limited Tel: + 44 (0) 20 7426 7736 

Paul Fincham 

Jonathan Becher 

Bankside Consultants Ltd Tel: + 44 (0) 20 7367 8888 

Simon Rothschild 

Oliver Winters 

 

Murray Consultants 

Ed Micheau  Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESSLFMASASEEW
Date   Source Headline
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan
15th Jan 20257:00 amRNSFirst robotic-guided lung ablation cases commence
16th Dec 20247:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.